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Aim: The aim of this study was to evaluate the prognostic value of
pretreatment 18f-fdg PET-CT in patients with hepatocarcinoma treated by
liver transplantation.
Methods: The authors retrospectively analyzed the data of 27 patients (mean
age 58 ! 9 years) who underwent FDG PET-CT before liver transplantation
for hepatocarcinoma. Mean follow-up was 26 ! 18 months. The FDG PET/CT
was performed according to a standard clinical protocol: 4 MBqFDG/kg body
weight, uptake 60 min, low-dose non-enhanced CT. The authors measured the
SUVmax and SUVmean of the tumor and the normal liver. The tumor/liver
activity ratios (RSUVmax and RSUVmean) were tested as prognostic factors
and compared to the following conventional prognostic factors: MILAN, CLIP,
OKUDA, TNM stage, alphafoetoprotein level, portal thrombosis, size of the
largest nodule, tumor differentiation, microvascular invasion, underlying
cirrhosis and liver function.
Results: Overall and recurrence free survivals were 80.7% and 67.4% at
3 years, and 77.4% and 67.4% at 5 years, respectively. According to a
multivariate Cox model, only 18f-fdg PET-CT RSUVmax predicted recurrence
free survival. Even though the MILAN criteria alone were not predictive, it is
worth noting that none of the patients outside the MILAN criteria and with
RSUVmax < 1.15 relapsed.
Conclusions: FDG PET/CT with a cut-off value of 1.15 is a strong prognostic
factor for recurrence and death in patients with HCC treated by liver
transplantation. Further prospective studies should test whether the metabolic
index should be systematically included in the preoperative assessment.
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Introduction: As the population of elderly patients with liver disease expands,
we are facing increasing numbers of transplant recipients from older age
groups. In this retrospective study we aimed to identify donor and recipient
factors associated with graft failure and patient mortality following liver
transplantation in recipients over 60 years of age.
Patients and methods: A retrospective study of prospectively collected data
was performed. Analyzed patients included first time, cadaveric liver-only
recipients aged over 60 years at the time of the transplant. The patients
(n = 138) were transplanted at a single center, between May 2007 and May
2013. Mean age of the patients in this group was 64 years of age (range 60–
77). After an average follow up of 34 months (range 12–72) from the transplant,
101 patients (73.2%) were alive with a functioning graft, 5 patients (3.6%) were
retransplanted and 37 patients (26.8%) died. Univariate and multivariate
analyses were performed to search for predictors of graft failure and patient
mortality.
Results: Recipient MELD over 25, male sex, acute liver failure and HCV
positivity were predictive of patient mortality, while increased incidence of graft
failure was seen in patients transplanted with livers from older donors.
Conclusion: In times of organ scarcity, optimal organ utilization is of utmost
importance. We believe our results can be used for better recipient selection
and improved graft to recipient matching in this challenging group of patients.
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Introduction: CD14s (Presepsin) has been identified as a protein whose
levels increase specifically in the blood of patients with bacterial infection.
Pathfast Assay System (PAS) is able to detect the levels of sCD14. In this
study, we evaluated the clinical performance of PAS and its usefulness in the
early diagnosis of bacterial infection in liver transplant (LT) recipients.
Materials: Twenty-five patients were enrolled in this study. Mean age of
patients was 52.5 years, 12 female and 13 male. The heparinized whole blood
for PAS was used in the evaluation of bacterial infection after 48 h of liver
transplant [T0]. The PAS was repeated after 48 h [T1]; at 96 h [T2]; at 144 h
[T3] than at 15 days [T4] for monitoring the clinical responses to therapeutic
interventions. Blood cultures were performed in all patients at moment that PAS
test was performed. The assay time was 15 min using a sample volume of
100 lL. A value >377 pg/mL was considered positive as indicated by
manufacturers.
Results: Twelve patients resulted positive to PAS. The mean sCD14 level
was 1045 ! 977 pg/mL. Microbiological findings confirmed the presence of
bacterial infections within 81 ! 3.2 h from enrolment in all 12 positive patients.
Presepsin level increased in five patients at [T1] and [T2]. These five patients
(31%) did not respond to empiric antibiotic treatment and the antibiotic therapy
was modified. When the PAS was performed, 41% of patients no showed signs
or symptoms of bacterial infection. At 30th day of follow up, the survival was
100% with a good graft function.
Conclusions: Early diagnosis is essential to improving the results of
treatment of infections in particular in LT recipients where infection represents
one of the primary barrier to success of transplant. PAS test highlighted a
significant performance, showing the presence of infection in a very short time
(15 min). A greater number of patients is necessary to confirm these data.
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Liver angiosarcoma (AS) is a high-malignant tumor, presenting usually at
advanced stages, what implies poor outcomes after conventional treatments
(surgical resection, chemotherapy) and also after liver transplantation (LT) (1).
Consequently, the latter is currently a contraindication, as quoted in an article
from the ELTR (2).
A 23-year-old man, with neither prior diseases nor toxic intake, presented
with sudden jaundice and hepatic decompensation. A complete study was
conducted in our LTUnit: contrast-enhancedCT, liver biopsy and viral and tumor
markers (both negative). Results were plausible with Budd-Chiari Syndrome
(BCS), severe abnormal liver function (MELD: 20). Consequently, the patient
was included in LT wait-list and one month later he was operated on.
Histopathology of the explant liver showed a primary diffuse AS (CD31 and
CD34 positive) with paediatric features (kaposiform cells), no extra-hepatic
extension. Post-transplant period was uneventful except for early acute renal
failure. Seven months after LT, the patient presented metastases in several
locations and graft dysfunction, which led to his death.
Diffuse AS has been exceptionally reported to mimick BCS (1,3). Due to
this, LT would be performed and it would only be possible to diagnose the
tumor during explant histological study, as occurred in our patient. Besides,
AS is uncommon among children and the early age of our patient was a factor
not suggesting this neoplasm. In fact, to the best of our knowledge,
histological paediatric form of AS in a 24 year-old patient has never been
reported to date.
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